Eva Guerra

534 total citations
22 papers, 150 citations indexed

About

Eva Guerra is a scholar working on Oncology, Reproductive Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eva Guerra has authored 22 papers receiving a total of 150 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Reproductive Medicine and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eva Guerra's work include Ovarian cancer diagnosis and treatment (13 papers), PARP inhibition in cancer therapy (9 papers) and Endometrial and Cervical Cancer Treatments (5 papers). Eva Guerra is often cited by papers focused on Ovarian cancer diagnosis and treatment (13 papers), PARP inhibition in cancer therapy (9 papers) and Endometrial and Cervical Cancer Treatments (5 papers). Eva Guerra collaborates with scholars based in Spain, Italy and Belgium. Eva Guerra's co-authors include Emilio Álvarez-Cuesta, Ricardo Madrigal‐Burgaleta, Antonio González-Martı́n, Ignacio Romero, María Pilar Berges‐Gimeno, Ana Santaballa, Andrés Poveda, Mansoor Raza Mirza, Ignace Vergote and Ana Oaknin and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and The Oncologist.

In The Last Decade

Eva Guerra

22 papers receiving 148 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Guerra Spain 8 88 70 29 29 23 22 150
Ilian Tchakov United Kingdom 8 149 1.7× 63 0.9× 73 2.5× 50 1.7× 33 1.4× 13 216
Anna Pawłowska Poland 10 126 1.4× 85 1.2× 60 2.1× 117 4.0× 16 0.7× 21 246
Daliah Tsoref Israel 6 59 0.7× 52 0.7× 66 2.3× 16 0.6× 23 1.0× 15 166
Saira Khalique United Kingdom 7 72 0.8× 96 1.4× 107 3.7× 23 0.8× 23 1.0× 11 193
Andrea Lindgren Sweden 7 41 0.5× 41 0.6× 42 1.4× 4 0.1× 30 1.3× 11 168
Elizabeth V. Connor United States 6 44 0.5× 26 0.4× 53 1.8× 13 0.4× 21 0.9× 12 156
Marzia Falanga Italy 8 103 1.2× 33 0.5× 67 2.3× 4 0.1× 84 3.7× 12 195
Eugenia Ortega Spain 6 44 0.5× 20 0.3× 42 1.4× 5 0.2× 25 1.1× 9 114
Maria Pilar Barretina-Ginesta Spain 6 53 0.6× 69 1.0× 49 1.7× 10 0.3× 14 0.6× 9 151
L. Morales Belgium 5 123 1.4× 13 0.2× 13 0.4× 27 0.9× 42 1.8× 10 183

Countries citing papers authored by Eva Guerra

Since Specialization
Citations

This map shows the geographic impact of Eva Guerra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Guerra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Guerra more than expected).

Fields of papers citing papers by Eva Guerra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Guerra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Guerra. The network helps show where Eva Guerra may publish in the future.

Co-authorship network of co-authors of Eva Guerra

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Guerra. A scholar is included among the top collaborators of Eva Guerra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Guerra. Eva Guerra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rey, José Manuel del, Cristina Saavedra, Diana Isabel Rosero, et al.. (2024). Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study. The Oncologist. 30(8). 1 indexed citations
3.
Marth, Christian, Marie‐Ange Mouret‐Reynier, Domenica Lorusso, et al.. (2023). #528 Efficacy of subsequent chemotherapy followed by PARP inhibitor maintenance in patients with advanced ovarian cancer in the phase III PAOLA-1/ENGOT-Ov25 trial. A21.1–A21. 7 indexed citations
4.
5.
Albarrán, Víctor, Jesús Chamorro, Javier Pozas, et al.. (2023). Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature. Frontiers in Oncology. 13. 1158981–1158981. 3 indexed citations
6.
Fidalgo, José Alejandro Pérez, Eva Guerra, Yolanda García García, et al.. (2023). Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601. International Journal of Gynecological Cancer. 33(6). 929–936. 3 indexed citations
7.
Romero, Ignacio, Belén Perez‐Mies, Andrés Redondo, et al.. (2023). The Prognostic Significance of Tumor-Infiltrating Lymphocytes, PD-L1, BRCA Mutation Status and Tumor Mutational Burden in Early-Stage High-Grade Serous Ovarian Carcinoma—A Study by the Spanish Group for Ovarian Cancer Research (GEICO). International Journal of Molecular Sciences. 24(13). 11183–11183. 2 indexed citations
8.
Harter, Philipp, Marie‐Ange Mouret‐Reynier, Domenica Lorusso, et al.. (2023). Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.. Journal of Clinical Oncology. 41(16_suppl). 5550–5550. 14 indexed citations
9.
Poveda, Andrés, Raquel López-Reig, Ana Oaknin, et al.. (2022). Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study. Cancers. 14(4). 915–915. 5 indexed citations
10.
Makker, Vicky, José Alejandro Pérez Fidalgo, Alice Bergamini, et al.. (2022). Randomized phase III study of maintenance selinexor versus placebo in endometrial cancer (ENGOT-EN5/GOG-3055/SIENDO): Impact of subgroup analysis and molecular classification.. Journal of Clinical Oncology. 40(16_suppl). 5511–5511. 9 indexed citations
11.
12.
Kristeleit, Rebecca, Víctor Moreno, Valentina Boni, et al.. (2021). Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study. International Journal of Gynecological Cancer. 31(11). 1428–1436. 6 indexed citations
13.
Italiano, Antoîne, Loïc Verlingue, Hans Prenen, et al.. (2021). Clinical activity and safety of simlukafusp alfa, an engineered interleukin-2 variant targeted to fibroblast activation protein-α, combined with atezolizumab in patients with recurrent or metastatic cervical cancer.. Journal of Clinical Oncology. 39(15_suppl). 5510–5510. 19 indexed citations
14.
Vergote, Ignace, José Alejandro Pérez Fidalgo, Erika Hamilton, et al.. (2021). SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. Journal of Clinical Oncology. 39(15_suppl). TPS5610–TPS5610. 6 indexed citations
15.
Scambia, Giovanni, Sileny Han, Amit M. Oza, et al.. (2020). Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) versus PAC alone in patients (pts) with advanced, recurrent, or persistent endometrial cancer.. Journal of Clinical Oncology. 38(15_suppl). 6087–6087. 7 indexed citations
16.
Romero, Ignacio, Ana Santaballa, Santiago González-Santiago, et al.. (2019). Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer. Anti-Cancer Drugs. 30(6). 628–635. 9 indexed citations
17.
Romero, Ignacio, María Jesús Rubio, Raquel Serrano, et al.. (2018). Preoperative olaparib in early-stage endometrial cancer (EC): A phase 0, window of opportunity trial to evaluate the PARP inhibition effect, targeting cell cycle-related proteins (POLEN study).. Journal of Clinical Oncology. 36(15_suppl). 5598–5598. 1 indexed citations
18.
Madrigal‐Burgaleta, Ricardo, et al.. (2017). Assessment of Antihistamines and Corticosteroids as Premedication in Rapid Drug Desensitization to Paclitaxel: Outcomes in 155 Procedures. The Journal of Allergy and Clinical Immunology In Practice. 6(4). 1356–1362. 19 indexed citations
19.
20.
Oaknin, Ana, Antonio González-Martı́n, Yolanda García García, et al.. (2012). A phase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): A Spanish Ovarian Cancer Group (GEICO) study.. Journal of Clinical Oncology. 30(15_suppl). 5068–5068. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ilian Tchakov Breakdown of academic impact, for papers by Anna Pawłowska Breakdown of academic impact, for papers by Daliah Tsoref Breakdown of academic impact, for papers by Saira Khalique Breakdown of academic impact, for papers by Andrea Lindgren Breakdown of academic impact, for papers by Elizabeth V. Connor Breakdown of academic impact, for papers by Marzia Falanga Breakdown of academic impact, for papers by Eugenia Ortega Breakdown of academic impact, for papers by Maria Pilar Barretina-Ginesta Breakdown of academic impact, for papers by L. Morales
Rankless by CCL
2026